List of Excipients in Branded Drug CHOLESTYRAMINE LIGHT

Generic Drugs Containing CHOLESTYRAMINE LIGHT

Company	Ingredient	NDC	Excipient
Eon Labs Inc	cholestyramine light	0185-0939	AMMONIUM GLYCYRRHIZATE
Eon Labs Inc	cholestyramine light	0185-0939	ANHYDROUS CITRIC ACID
Eon Labs Inc	cholestyramine light	0185-0939	ASPARTAME
Eon Labs Inc	cholestyramine light	0185-0939	D&C YELLOW NO. 10
Eon Labs Inc	cholestyramine light	0185-0939	FD&C YELLOW NO. 6
Eon Labs Inc	cholestyramine light	0185-0939	FRUCTOSE
Eon Labs Inc	cholestyramine light	0185-0939	MANNITOL

What are the Most Frequently-Used Excipients in CHOLESTYRAMINE LIGHT?

# Of NDCs	Excipient
5	AMMONIUM GLYCYRRHIZATE
7	ANHYDROUS CITRIC ACID
7	ASPARTAME
6	D&C YELLOW NO. 10
1	D&C YELLOW NO. 10 ALUMINUM LAKE
7	FD&C YELLOW NO. 6
5	FRUCTOSE

Cholestyramine Light Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Cholestyramine light is a mature, nonabsorbed bile acid sequestrant supplied as an oral powder for suspension. Its commercial value depends less on active-ingredient exclusivity and more on excipient selection, palatability, suspension performance, dose uniformity, packaging, and patient adherence. The strongest opportunities are sugar-free and low-calorie formulations, improved flavor systems, single-dose packaging, pediatric and specialty-care presentations, and region-specific products for hypercholesterolemia and cholestatic pruritus.

What is cholestyramine light and how is it regulated?

Cholestyramine light is a low-density form of cholestyramine anion-exchange resin. The resin binds bile acids in the gastrointestinal tract and is not systemically absorbed under normal use. The drug is administered after dispersion in water or another approved liquid rather than being swallowed dry.

In the United States, cholestyramine powder for oral suspension is regulated as a prescription drug. FDA-approved products include branded and generic versions of cholestyramine resin powder for oral suspension. Approved uses include:

• Reduction of elevated low-density lipoprotein cholesterol.
• Treatment of pruritus associated with partial biliary obstruction.
• Selected off-label uses involving bile acid malabsorption and diarrhea.

The formulation is technically demanding because the product must disperse sufficiently for dosing without dissolving. The resin's particle-size distribution, bulk density, moisture content, flowability, and electrostatic behavior affect both manufacturing and patient use.

Attribute	Commercial implication
Nonabsorbed resin	Conventional systemic bioequivalence is less informative than suspension and binding performance
Powder for suspension	Requires controlled wetting, dispersion, and dose withdrawal
High dose volume	Palatability and packaging directly affect adherence
Drug-drug binding	Labeling and administration instructions are central to product value
Low-density resin	Requires specialized powder handling and fill-weight controls
Mature active ingredient	Limited opportunity for composition-of-matter exclusivity

The term "light" generally refers to the physical grade of cholestyramine resin rather than a lower pharmacologic dose. The marketed dose is commonly expressed as 4 grams of cholestyramine resin per packet or dose unit, although the total powder weight is higher because of excipients.

What excipients are used in cholestyramine light products?

Commercial cholestyramine products use excipients for sweetness, flavor, wetting, suspension, flow, appearance, and manufacturing control. The exact composition varies by manufacturer and product presentation.

Common excipient classes include:

Excipient function	Representative materials	Development purpose
Sweetener and bulking agent	Sucrose, saccharin sodium, aspartame, sucralose	Masks resin taste and increases consumer acceptability
Acidulant	Citric acid	Provides flavor balance and may improve perceived freshness
Flavor system	Orange, citrus, fruit, or specialty flavors	Reduces bitterness, chalkiness, and resin-associated mouthfeel
Wetting and dispersing agent	Polysorbate 80 and related systems	Improves powder wetting and dispersion in liquid
Suspending or viscosity agent	Acacia, xanthan gum, propylene glycol alginate	Reduces rapid settling and supports dose uniformity
Colorant	FD&C or D&C color additives	Supports product identification and flavor signaling
Processing aids	Anti-caking and flow-control materials, where justified	Improves filling, blending, and content uniformity

The reference-product excipient profile matters for an abbreviated new drug application because formulation differences can affect performance, tolerability, labeling, and regulatory review. A generic product does not necessarily need to duplicate every inactive ingredient, but it must satisfy applicable pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

What excipient strategy best improves cholestyramine light?

The best strategy is to treat excipient selection as a performance program rather than a flavoring exercise. Four formulation attributes should drive development.

Palatability

Cholestyramine has a distinctive resinous mouthfeel and can be difficult for patients to take consistently. Flavor systems should be evaluated in the actual use vehicle, not only as dry powders. Water, juice, and soft foods can produce different bitterness, sweetness, and aftertaste profiles.

A practical development program should compare:

• Citrus and orange systems.
• Berry and tropical systems.
• Reduced-sugar and sugar-free systems.
• Sweetener combinations that limit lingering aftertaste.
• Flavor systems compatible with pediatric and geriatric use.

Flavor masking cannot compromise dispersion. Hydrophobic flavor oils may slow wetting or promote floating particles. The final formulation requires testing after storage, because flavor volatility and sweetener degradation can change the sensory profile.

Suspension performance

The product must disperse rapidly and remain sufficiently uniform during the patient's dosing interval. Excessive viscosity can make the product difficult to drink or transfer from the container. Insufficient viscosity can allow rapid settling and create dose nonuniformity.

The target is not a permanently homogeneous suspension. The target is rapid wetting, reproducible dispersion, adequate hold time, and easy redispersion before administration.

Key tests include:

• Wetting time.
• Dispersion time.
• Sedimentation rate.
• Redispersibility.
• Particle-size distribution.
• Dose uniformity after standing.
• Residual powder on the cup or packet.
• Performance in labeled administration vehicles.

Acacia, xanthan gum, and propylene glycol alginate can improve suspension behavior, but each can increase viscosity, alter mouthfeel, or affect filling and reconstitution. A low-viscosity system with strong wetting performance may be more commercially attractive than a highly viscous suspension.

Sugar and calorie reduction

Traditional cholestyramine products may use sucrose to improve taste and provide powder bulk. A sugar-free version can address patients with diabetes, metabolic disease, or calorie-restricted diets. It can also support institutional purchasing where sugar content is a formulary consideration.

The main challenges are:

• Sweetener aftertaste.
• Increased bitterness perception when sucrose is removed.
• Bulk-density changes.
• Moisture sensitivity.
• Potential laxative effects from certain polyols.
• Labeling implications for phenylalanine-containing sweeteners such as aspartame.

A sugar-free formulation should not simply substitute one sweetener for another. The replacement must be evaluated with the resin, acidulant, flavor, and suspension polymer as a complete system.

Administration convenience

Cholestyramine is typically taken multiple times per day and must be separated from several other oral medicines. Single-dose sachets can improve portability, reduce measuring errors, and support adherence. Unit-dose packaging also creates opportunities for hospital, long-term-care, and specialty-pharmacy distribution.

Packaging should control:

• Moisture ingress.
• Powder caking.
• Static charge.
• Fill-weight variability.
• Seal integrity.
• Ease of opening for patients with limited dexterity.

A bottle presentation may reduce packaging cost, while sachets provide better dose control and convenience. The optimal commercial strategy may use both formats.

What formulations are protected by cholestyramine light patents?

Cholestyramine light has limited modern patent protection compared with new chemical entities or complex biologics. The active resin is an established pharmaceutical ingredient, and the principal commercial barriers are formulation quality, manufacturing know-how, regulatory compliance, and brand positioning.

Potentially protectable subject matter includes:

• Specific excipient combinations.
• Sugar-free flavor systems.
• Low-viscosity suspension compositions.
• Improved wetting and redispersion systems.
• Moisture-resistant sachets.
• Unit-dose packaging configurations.
• Pediatric administration vehicles.
• Products optimized for administration with selected foods or beverages.
• Manufacturing processes that improve blend uniformity or reduce caking.

A formulation patent must show more than the routine substitution of one flavor, sweetener, or suspending agent. Stronger claims would be supported by unexpected improvements in stability, suspension uniformity, palatability, dose recovery, or adherence-related performance.

The most defensible protection is likely to be narrow and data-driven. Broad claims covering cholestyramine with common sweeteners, flavors, or gums would face substantial validity and obviousness risk.

When does cholestyramine light lose exclusivity?

The underlying drug has no meaningful new-molecule exclusivity remaining. Cholestyramine products have been marketed for decades, and generic competition is established in major markets.

Exclusivity category	Current commercial assessment
New chemical entity exclusivity	Expired
Original composition-of-matter protection	Expired or commercially irrelevant
Pediatric exclusivity	No material current barrier identified
Orphan exclusivity	Not applicable to the general product
Biosimilar exclusivity	Not applicable
Formulation exclusivity	Possible only for a specific later-developed product
Method-of-use exclusivity	Limited practical value unless tied to a differentiated approved indication
Regulatory exclusivity for a new product	Potentially available for a qualifying reformulation, but not inherent in cholestyramine light

The timing of generic entry is therefore driven by FDA approval, manufacturing readiness, supply economics, and any product-specific formulation or method-of-use patents rather than by the historical active ingredient.

What is the Orange Book status of cholestyramine light?

FDA Orange Book treatment focuses on approved prescription drug products, therapeutic equivalence, patents, and applicable exclusivity. Cholestyramine powder for oral suspension products are generally evaluated as conventional multisource products rather than as biologic products.

Commercial diligence should distinguish among:

1. The reference listed drug.
2. Approved generic powders for oral suspension.
3. Product-specific patents listed for a particular brand.
4. Patents covering a formulation or delivery system but not listed in the Orange Book.
5. Unlisted process, packaging, trade-secret, and know-how protections.

A formulation developer should not assume that the absence of a major Orange Book barrier eliminates all risk. A product can face freedom-to-operate issues involving manufacturing processes, packaging, trademarks, or non-Orange-Book patents. The reverse is also true: a listed patent does not necessarily prevent all noninfringing generic design options.

Are Paragraph IV challenges likely for cholestyramine light?

Paragraph IV activity is less commercially significant for mature cholestyramine products than for recently approved drugs. The active ingredient and conventional powder dosage form are well established. A Paragraph IV challenge would be more likely to target a specific branded formulation, delivery system, or method-of-use claim than the basic cholestyramine resin composition.

A generic applicant could pursue:

• A formulation matching the reference product closely enough for ANDA approval.
• A design-around formulation with different flavors, sweeteners, or suspending agents.
• A 505(b)(2) pathway for a differentiated presentation or new administration method.
• A product directed to an approved use with distinct labeling, where legally permissible.

The principal litigation exposure would arise from narrow formulation claims, data exclusivity for a later product, or allegations involving a branded product's listed patents. The base cholestyramine resin market has limited structural protection against generic entry.

What generic launch risks exist for cholestyramine light?

Generic launch risk is high because the product is mature and the active ingredient is inexpensive. The main constraints are operational rather than legal.

Manufacturing risks

Low-density resin can create:

• Powder segregation during blending.
• Static and dust-control problems.
• Variable fill weights.
• Caking under elevated humidity.
• Inconsistent dispersion after storage.
• Difficulties scaling from laboratory to commercial equipment.

Manufacturers need validated controls for raw-material particle size, bulk density, moisture, blending time, and filling conditions.

Regulatory risks

A generic applicant must demonstrate that the product meets applicable quality and equivalence requirements. Reformulation can create review issues if excipients alter:

• Dosage uniformity.
• Suspension properties.
• Drug-drug binding behavior.
• Labeling instructions.
• Allergen or food-sensitivity disclosures.
• Use in pediatric or diabetic populations.

Commercial risks

Price competition can reduce margins quickly. Differentiation must therefore be based on measurable value:

• Better taste.
• Lower sugar content.
• Smaller dose volume.
• Easier packet opening.
• Improved portability.
• Better supply reliability.
• Hospital and long-term-care packaging.
• Specialty distribution for cholestatic pruritus.

What commercial opportunities exist for cholestyramine light excipients?

Sugar-free and diabetic-friendly products

A sugar-free product has the clearest broad-market opportunity. The formulation should use a sweetener system with a low aftertaste burden and avoid excessive viscosity or gastrointestinal intolerance.

Pediatric and caregiver-friendly products

Cholestyramine is difficult for children to take because of taste, texture, and dosing frequency. A pediatric-oriented product could use:

• Lower-volume sachets.
• Fruit flavor systems.
• Improved wetting.
• Dose-marked packets.
• Compatibility with approved soft foods or beverages.
• Caregiver instructions designed to reduce missed doses.

Any pediatric positioning would require appropriate clinical, labeling, and regulatory support. A child-friendly taste profile alone would not establish a new approved pediatric indication.

Specialty products for cholestatic pruritus

Patients with cholestatic disease may use cholestyramine for symptom control even when lipid lowering is not the primary objective. Specialty pharmacy and hepatology channels may value reliable supply, tolerability, and packaging more than low unit price.

Institutional and long-term-care packaging

Unit-dose sachets can reduce administration errors and simplify medication carts. A product with clear preparation instructions and low residue could compete in hospitals, nursing facilities, and home-care settings.

Global-market adaptations

Excipient strategy should reflect local requirements:

• Sugar restrictions and diabetes prevalence.
• Permitted colorants.
• Local flavor preferences.
• Excipient monograph standards.
• Sachet and labeling requirements.
• Climate-zone stability, particularly humidity.
• Availability of pharmaceutical-grade polymers and flavors.

A product designed for humid markets may need higher-barrier packaging and stronger anti-caking controls than a product intended for dry climates.

How does cholestyramine light compare with other bile acid sequestrants?

Product class	Formulation advantage	Commercial limitation
Cholestyramine powder	Established efficacy, low ingredient cost, broad manufacturing familiarity	Poor palatability, large dose, suspension inconvenience
Colestipol granules or tablets	Alternative bile acid sequestrant formats	Similar gastrointestinal and adherence concerns
Colesevelam tablets	Greater convenience and improved tolerability for some patients	Higher cost and tablet burden
Liquid or ready-to-use suspension	Convenience and reduced preparation steps	Stability, packaging, shipping, and preservative challenges

Cholestyramine remains economically attractive where cost is the primary consideration. Colesevelam competes more effectively on convenience and tolerability. An improved cholestyramine light product should therefore target the specific weaknesses that drive switching: taste, preparation time, mess, and portability.

How strong is the patent estate for cholestyramine light?

The base patent estate is weak from a modern exclusivity perspective. A commercially relevant estate would need to focus on later-developed formulation or packaging claims supported by comparative data.

Protection type	Relative strength
Cholestyramine active ingredient	Weak because of long market history
Conventional powder formulation	Weak to moderate, depending on claim specificity
Novel sugar-free system	Moderate if supported by unexpected performance
Improved suspension technology	Moderate if tied to measurable dose-uniformity benefits
Moisture-barrier sachet	Moderate but vulnerable to design-around
Manufacturing process	Moderate as trade secret; patent strength depends on process specificity
Method of use	Limited unless the indication or dosing regimen is differentiated
Trademark and trade dress	Potentially useful for commercial positioning but separate from patent exclusivity

The most valuable protection may be a package of narrow formulation patents, manufacturing know-how, supplier controls, trademarks, and distribution agreements rather than a single broad patent.

What licensing deals and partnerships are commercially relevant?

The mature market is more likely to support supply and formulation partnerships than large discovery-stage licensing transactions. Relevant deal structures include:

• Long-term supply agreements for pharmaceutical-grade cholestyramine resin.
• Contract manufacturing agreements for sachet filling.
• Flavor-house partnerships for proprietary citrus or fruit systems.
• Excipient supplier agreements for low-moisture suspending agents.
• Regional licensing for branded sugar-free products.
• Co-development agreements with specialty pharmacies or hospital distributors.
• Private-label manufacturing for institutional buyers.

A partner with validated low-density powder handling may be more valuable than a partner with a nominally proprietary excipient. Manufacturing execution is a material source of competitive advantage in this product category.

What regulatory pathway is best for a new cholestyramine light product?

The pathway depends on the product's relationship to an approved reference product.

An ANDA is generally the most efficient route for a conventional generic product that can meet applicable equivalence and labeling requirements. A 505(b)(2) application may be more suitable for a meaningfully differentiated product involving a new formulation, delivery system, administration vehicle, or other change requiring reliance on existing FDA findings combined with new data.

A reformulation program should establish:

• Raw-material specifications.
• Resin identity and particle-size controls.
• Excipient compatibility.
• Blend uniformity.
• Moisture and thermal stability.
• Suspension and redispersion performance.
• Dose recovery from the administration container.
• Drug-binding or adsorption performance, where relevant.
• In vitro interaction behavior with coadministered medicines.
• Labeling and human-factors performance.

FDA-approved labeling remains central because cholestyramine can interfere with absorption of other medicines. Administration instructions commonly require other oral drugs to be taken at a separated time interval. A product that improves convenience but creates confusion about separation rules could increase regulatory and commercial risk.

Key Takeaways

• Cholestyramine light is a mature, nonabsorbed resin product with limited active-ingredient exclusivity.
• Excipient strategy should prioritize palatability, wetting, suspension uniformity, low sugar, and packaging convenience.
• Sugar-free, fruit-flavored, unit-dose, and caregiver-friendly products offer the clearest commercial opportunities.
• The strongest intellectual-property position would likely combine narrow formulation claims with manufacturing know-how and packaging controls.
• Generic entry risk is high because the active ingredient and dosage form are established.
• Manufacturing performance, supply reliability, and patient adherence are more important competitive variables than composition-of-matter patents.
• An ANDA is generally suited to a conventional generic; a differentiated formulation may require a 505(b)(2) strategy.
• Biosimilar risk is irrelevant because cholestyramine is a small-molecule resin drug, not a biologic.

FAQs

Can cholestyramine light be reformulated without changing the active resin?

Yes. Developers can change flavor, sweetener, suspending agent, wetting agent, color, or packaging, subject to equivalence, quality, labeling, and regulatory requirements.

Is a sugar-free cholestyramine product commercially attractive?

Yes. Sugar-free positioning can address patients with diabetes, calorie restrictions, or concerns about repeated daily sucrose exposure. The main technical challenge is maintaining acceptable taste and suspension performance.

Does cholestyramine light require a preservative?

Not necessarily. A dry powder supplied for dispersion immediately before use may not require the same preservative system as a ready-to-use liquid. The final requirement depends on formulation design, moisture exposure, microbiological risk, packaging, and labeled in-use conditions.

Can cholestyramine light be sold over the counter?

In the United States, established cholestyramine products are generally prescription products. An over-the-counter switch would require an FDA regulatory pathway and consumer-use data supporting safe self-selection, labeling comprehension, and appropriate use.

What is the main barrier to launching a new cholestyramine light product?

The primary barrier is achieving reproducible powder manufacturing and patient-acceptable administration at a price that supports commercial distribution. Patent exclusivity is usually a secondary issue.

References

1. U.S. Food and Drug Administration. (2024). Questran (cholestyramine for oral suspension) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. National Library of Medicine. (2024). Cholestyramine powder for suspension drug labels. DailyMed.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin. FDA.